NASDAQ:NDRM - NeuroDerm Ltd. - Ordinary Share Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$38.85
+0.30 (1.20%)
Get New NeuroDerm Ltd. - Ordinary Share Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NDRM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NDRM

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for NeuroDerm Ltd. - Ordinary Share in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a -100.00% upside from the last price of $38.85.

This chart shows the closing price for NDRM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in NeuroDerm Ltd. - Ordinary Share. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/27/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/14/2017Jefferies Financial GroupReiterated RatingBuy$42.00Low
8/2/2017Roth CapitalDowngradeBuy ➝ Neutral$33.00 ➝ $39.00Low
7/24/2017Raymond JamesDowngradeOutperform ➝ Market Perform$39.00High
7/21/2017Deutsche Bank AktiengesellschaftInitiated CoverageBuy ➝ Buy$47.00High
6/14/2017Roth CapitalSet Price TargetBuy$33.00Low
6/14/2017CIBCUpgradeMarket Perform ➝ Outperform$42.00High
6/14/2017OppenheimerUpgradeMarket Perform ➝ Outperform$42.00High
(Data available from 5/22/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/24/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/22/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/21/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/23/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/22/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/22/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
NeuroDerm Ltd. - Ordinary Share logo
NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson's disease, as well as other CNS diseases. The Company's Parkinson's disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages. Its liquid LD/CD and apomorphine formulations include ND0612H, ND0612L and ND0701. It is developing ND0612H for the treatment of patients suffering from severe Parkinson's disease. It is developing ND0612L for the treatment of patients at the moderate stage of Parkinson's disease that can no longer control motor complications with oral levodopa. It has also designed ND0701, which is an apomorphine-based product. ND0701 is for patients suffering from Parkinson's disease, may be used mostly by patients suffering from high motor fluctuations and not responding well to LD/CD.
Read More

Today's Range

Now: $38.85
Low: $38.85
High: $38.85

50 Day Range

MA: N/A

52 Week Range

Now: $38.85
Low: $15.20
High: $38.95

Volume

N/A

Average Volume

418,712 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of NeuroDerm Ltd. - Ordinary Share?

The following Wall Street analysts have issued reports on NeuroDerm Ltd. - Ordinary Share in the last twelve months:
View the latest analyst ratings for NDRM.

What is the current price target for NeuroDerm Ltd. - Ordinary Share?

0 Wall Street analysts have set twelve-month price targets for NeuroDerm Ltd. - Ordinary Share in the last year.
View the latest price targets for NDRM.

What is the current consensus analyst rating for NeuroDerm Ltd. - Ordinary Share?

NeuroDerm Ltd. - Ordinary Share currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for NDRM.

How do I contact NeuroDerm Ltd. - Ordinary Share's investor relations team?

NeuroDerm Ltd. - Ordinary Share's physical mailing address is 3 Pekeris Street, Ruhrberg Science Bldg. Rabin Science Park Bell Entrance, REHOVOT, 7670212, Israel. The biotechnology company's listed phone number is +972-8-9462729. The official website for NeuroDerm Ltd. - Ordinary Share is neuroderm.com. Learn More about contacing NeuroDerm Ltd. - Ordinary Share investor relations.